Author Correction: Lysosomal and synaptic dysfunction markers in longitudinal cerebrospinal fluid of de novo Parkinson’s disease
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Author Correction: Lysosomal and synaptic dysfunction markers in longitudinal cerebrospinal fluid of de novo Parkinson’s disease ; volume:10 ; number:1 ; day:25 ; month:6 ; year:2024 ; pages:1 ; date:12.2024
npj Parkinson's Disease ; 10, Heft 1 (25.6.2024), 1, 12.2024
- Urheber
-
Bartl, Michael
Nilsson, Johanna
Dakna, Mohammed
Weber, Sandrina
Schade, Sebastian
Xylaki, Mary
Fernandes Gomes, Bárbara
Ernst, Marielle
Muntean, Maria-Lucia
Sixel-Döring, Friederike
Trenkwalder, Claudia
Zetterberg, Henrik
Brinkmalm, Ann
Mollenhauer, Brit
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41531-024-00726-x
- URN
-
urn:nbn:de:101:1-2409152112067.235147954410
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:33 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Bartl, Michael
- Nilsson, Johanna
- Dakna, Mohammed
- Weber, Sandrina
- Schade, Sebastian
- Xylaki, Mary
- Fernandes Gomes, Bárbara
- Ernst, Marielle
- Muntean, Maria-Lucia
- Sixel-Döring, Friederike
- Trenkwalder, Claudia
- Zetterberg, Henrik
- Brinkmalm, Ann
- Mollenhauer, Brit
- SpringerLink (Online service)
Ähnliche Objekte (12)
Lysosomal and synaptic dysfunction markers in longitudinal cerebrospinal fluid of de novo Parkinson’s disease
Cerebrospinal fluid concentrations of inflammatory markers in Parkinson’s disease and atypical parkinsonian disorders
Neuroimaging and fluid biomarkers in Parkinson’s disease in an era of targeted interventions
Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer’s and Parkinson’s disease
Neurofilament light chain as neuronal injury marker – what is needed to facilitate implementation in clinical laboratory practice?
Detection of subarachnoid haemorrhage with spectrophotometry of cerebrospinal fluid – a comparison of two methods
Cerebrospinal Fluid Concentrations of the Synaptic Marker Neurogranin in Neuro-HIV and Other Neurological Disorders
Serum neurofilament light at diagnosis: a prognostic indicator for accelerated disease progression in Parkinson’s Disease
Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson’s disease with dementia and dementia with Lewy bodies compared to Alzheimer’s disease
Blood-based biomarkers in Alzheimer’s disease – moving towards a new era of diagnostics
Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics
Blood-based molecular biomarkers for Alzheimer’s disease
Lysosomal and synaptic dysfunction markers in longitudinal cerebrospinal fluid of de novo Parkinson’s disease
Cerebrospinal fluid concentrations of inflammatory markers in Parkinson’s disease and atypical parkinsonian disorders
Neuroimaging and fluid biomarkers in Parkinson’s disease in an era of targeted interventions
Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer’s and Parkinson’s disease
Neurofilament light chain as neuronal injury marker – what is needed to facilitate implementation in clinical laboratory practice?
Detection of subarachnoid haemorrhage with spectrophotometry of cerebrospinal fluid – a comparison of two methods
Cerebrospinal Fluid Concentrations of the Synaptic Marker Neurogranin in Neuro-HIV and Other Neurological Disorders
Serum neurofilament light at diagnosis: a prognostic indicator for accelerated disease progression in Parkinson’s Disease
Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson’s disease with dementia and dementia with Lewy bodies compared to Alzheimer’s disease
Blood-based biomarkers in Alzheimer’s disease – moving towards a new era of diagnostics
Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics
Blood-based molecular biomarkers for Alzheimer’s disease
Lysosomal and synaptic dysfunction markers in longitudinal cerebrospinal fluid of de novo Parkinson’s disease
Cerebrospinal fluid concentrations of inflammatory markers in Parkinson’s disease and atypical parkinsonian disorders
Neuroimaging and fluid biomarkers in Parkinson’s disease in an era of targeted interventions
Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer’s and Parkinson’s disease
Neurofilament light chain as neuronal injury marker – what is needed to facilitate implementation in clinical laboratory practice?
Detection of subarachnoid haemorrhage with spectrophotometry of cerebrospinal fluid – a comparison of two methods
Cerebrospinal Fluid Concentrations of the Synaptic Marker Neurogranin in Neuro-HIV and Other Neurological Disorders
Serum neurofilament light at diagnosis: a prognostic indicator for accelerated disease progression in Parkinson’s Disease
Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson’s disease with dementia and dementia with Lewy bodies compared to Alzheimer’s disease
Blood-based biomarkers in Alzheimer’s disease – moving towards a new era of diagnostics
Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics